-
Hidden worries in the development of volume procurement: supply cuts, medium-sized enterprises out, procurement fragmentation...
Time of Update: 2021-04-14
Pharmaceutical companies are busy dealing with various centralized procurement projects, not to mention which products will be included in the future, just say that after the selection, the supply of enterprises and the clinical replacement of hospitals, are all these smooth?
-
EMA accepts Bristol-Myers Squibb Opdivo Class II change application
Time of Update: 2021-04-14
The results showed that: (1) In all randomized patients (ITT), compared with placebo, adjuvant Opdivo treatment almost doubled the disease-free survival: the median DFS in the placebo group was 10.
-
Yangtze River Health: Ceftazidime for injection in its subsidiary passed the consistency evaluation
Time of Update: 2021-04-14
Ceftazidime for injection belongs to the third-generation cephalosporin antibiotic.
It also has a good antibacterial effect against nitrate-negative bacilli and Alcaligenes.
Ceftazidime for injection is a commonly used third-generation cephalosporin drug in clinical practice, and the two specifications of 0.
-
The blockbuster policy of Chinese medicine is coming, and the entire chain of listed chains has become popular
Time of Update: 2021-04-14
Medical News, April 1st, 30th, the listed chain has an eye-catching performance in the capital market. As of today's close, Yixintang has risen as much as 8. 98%. This is the most obvious signal th
-
A number of well-known pharmaceutical company executives leave the market to promote transformation
Time of Update: 2021-04-14
The market promotes transformation, and executives change frequently From the perspective of position, deputy general managers and vice presidents are the positions that senior executives of domestic pharmaceutical companies resign intensively; from the perspective of the reasons for resignation, it is mainly due to "personal reasons", followed by "work reasons.
-
Compaq's KHB-1802 project was suspended, can Langmu gain a foothold in the international market?
Time of Update: 2021-04-14
On the evening of March 28, Kanghong Pharmaceutical issued an announcement stating that the French National Agency for the Safety of Medicines and Health Products (hereinafter referred to as ANSM) has currently suspended "a multi-center, double-blind, randomized, dose range trial to evaluate conbercept eye The efficacy and safety of injection in the treatment of patients with neovascular age-related macular degeneration" Clinical Trial Project Trial 2 (KHB-1802).
-
Teresa's first-line treatment of NSLCL indications will be approved by medical insurance and will be approved for postoperative adjuvant treatment of lung cancer
Time of Update: 2021-04-14
In China, osimertinib was first approved by the NMPA in March 2017 for use in adult patients with locally advanced or metastatic NSCLC who have experienced disease progression during or after treatment with EGFR-TKIs, and have been tested to confirm the presence of EGFR T790M mutation-positive adult patients with locally advanced or metastatic NSCLC , The product name is Teresa, and it was included in the national medical insurance in 2018.
-
Jimin Trust's New Coronary Neutralizing Antibody Obtains Clinical Approval from U.S. FDA
Time of Update: 2021-04-14
One of the key steps for the new coronavirus to infect human cells is the receptor binding domain (RBD) of the S1 subunit of the virus surface spike protein (S protein) and the angiotensin II converting enzyme 2 (ACE2) on the surface of human cells.
-
The second batch of medical insurance key monitoring list is here!
Time of Update: 2021-04-14
Since Fujian Province has clearly strengthened the management of key monitoring drugs for medical insurance, two batches of lists have been issued one after another.
Since Fujian Province has clearly strengthened the management of key monitoring drugs for medical insurance, two batches of lists have been issued one after another.
-
Jinlida granules increase brown fat, regulate glucose and lipid metabolism and prevent diabetes
Time of Update: 2021-04-14
Jinlida granules can convert white fat into brown fat, reduce weight and improve glucose and lipid metabolismIn the next report, Academician Ning Guang reviewed the research results of Chinese researchers in the field of diabetes prevention and treatment in Chinese medicine, and focused on the evidence-based research of the patented Chinese medicine Jinlida granules developed under the guidance of collateral disease theory.
-
What are the ways to go to support domestically-made innovative drugs?
Time of Update: 2021-04-14
As a representative of the early domestic innovative drugs, the once-hot-selling antihypertensive compound reserpine and triamterene tablets (formerly known as Beijing Jiangya No.
-
Hengrui Medicine Mycophenolate Sodium Enteric-coated Tablets Officially Approved
Time of Update: 2021-04-14
On March 31, the official website of NMPA showed that Chengdu Shengdi, a subsidiary of Hengrui Pharmaceuticals, was officially approved for mycophenolate sodium enteric-coated tablets, which became the first domestic imitation of the product.
According to the Insight database, only the original research company of mycophenolate sodium has been approved for listing in China.
-
Over 130 drugs were sold for weight loss, outsourcing and other main themes
Time of Update: 2021-04-14
Medical News, April 2nd. Multinational pharmaceutical companies are generally more practical. According to their own development strategies, they consciously divest some "old" non-profitable busine
-
Medical representatives are difficult
Time of Update: 2021-04-14
Multi-party standardization of the practice of medical representativesTo a certain extent, the reduction of promotion costs by pharmaceutical companies has made it more difficult to carry out the work of medical representatives.
With the normalization of centralized procurement, the promotion costs of related products involving pharmaceutical companies are expected to be further reduced.
-
The release of major Chinese medicine documents affects all pharmaceutical companies...
Time of Update: 2021-04-14
"Regulations" clearly, city development and reform, economic information, Chinese Medicine, the drug regulatory authorities shall take measures to support traditional Chinese medicine production enterprises commonly used in large-scale Chinese herbal medicines in the construction of authentic traditional Chinese medicine origin, standardization, industrialization of plant breeding base , Promote the use of fine varieties and improve the quality of Chinese medicinal materials.
-
A batch of drugs were investigated: Fengre Ganmao Granules, Ganmaoling Granules...
Time of Update: 2021-04-14
Jiangxi: Several commonly used drugs were investigated and punished Coincidentally, just a few days ago, the Jiangxi Provincial Food and Drug Administration issued the 2021 Phase 2 Drug Supervision Sampling Information Announcement (hereinafter referred to as the "Announcement").
-
AstraZeneca/Daiichi Sankyo launches global phase 2 clinical trial: Enhertu treats HER2 mutant lung cancer
Time of Update: 2021-04-14
The trial was carried out in patients with metastatic non-small cell lung cancer (NSCLC) with HER2 mutations during or after receiving at least one previous platinum-containing treatment regimen, and evaluated the targeted antibody conjugate (ADC) Enhertu (trastuzumab).
-
The National Health Commission made it clear: encourage the production of reusable consumables
Time of Update: 2021-04-14
"Recommendations for the Catalog of Disposable Devices", the National Health Commission stated that the one-time use of high-value medical consumables may cause waste of resources, environmental pollution and rising medical costs.
-
Yangtze River acquires the right to develop and sell Daewoong Pharmaceutical's fexuprazan in China through a new 2.2 billion yuan agreement
Time of Update: 2021-04-14
According to the agreement, Haini Pharmaceuticals will be responsible for the clinical development of fexuprazan for the treatment of digestive system diseases, and will be responsible for the entire approval process of the drug in China.
-
State Council Information Office: Seven key tasks of Chinese medicine in the "14th Five-Year Plan"!
Time of Update: 2021-04-14
It is understood that during the "14th Five-Year Plan" period, multiple ministries and commissions at the national level will focus on inheriting the essence, maintaining integrity and innovation, deepening reform and improving the system as the driving force, insisting on giving full play to the characteristic advantages and multiple values of Chinese medicine, and insisting on highlighting Chinese medicine medical services The core value helps a healthy China.
